Alfred Zimmerlin
Overview
Explore the profile of Alfred Zimmerlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
346
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schutzius G, Kolter C, Bergling S, Tortelli F, Fuchs F, Renner S, et al.
Nat Chem Biol
. 2021 Jan;
17(3):280-290.
PMID: 33462494
Although most acute skin wounds heal rapidly, non-healing skin ulcers represent an increasing and substantial unmet medical need that urgently requires effective therapeutics. Keratinocytes resurface wounds to re-establish the epidermal...
2.
Walles M, Brown A, Zimmerlin A, End P
Chem Res Toxicol
. 2020 Jun;
33(7):1551-1560.
PMID: 32525307
Drug-induced liver injury (DILI) remains one of the key challenges in drug development due to the mechanisms of action being multifactorial in nature. This is particularly the case for idiosyncratic...
3.
Angst D, Gessier F, Janser P, Vulpetti A, Walchli R, Beerli C, et al.
J Med Chem
. 2020 Feb;
63(10):5102-5118.
PMID: 32083858
Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent...
4.
Pulz R, Angst D, Dawson J, Gessier F, Gutmann S, Hersperger R, et al.
ACS Med Chem Lett
. 2019 Oct;
10(10):1467-1472.
PMID: 31620235
Bruton's tyrosine kinase (BTK) is a member of the TEC kinase family and is selectively expressed in a subset of immune cells. It is a key regulator of antigen receptor...
5.
Zimmerlin A, Kiffe M
Drug Discov Today Technol
. 2013 Nov;
10(1):e191-8.
PMID: 24175349
New enabling MS technologies have made it possible to elucidate metabolic pathways present in ex vivo (blood, bile and/or urine) or in vitro (liver microsomes, hepatocytes and/or S9) samples. When...
6.
Hoepfner D, Karkare S, Helliwell S, Pfeifer M, Trunzer M, De Bonnechose S, et al.
Antimicrob Agents Chemother
. 2012 May;
56(8):4233-40.
PMID: 22615293
Systemic life-threatening fungal infections represent a significant unmet medical need. Cell-based, phenotypic screening can be an effective means of discovering potential novel antifungal compounds, but it does not address target...
7.
Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, et al.
J Med Chem
. 2011 Sep;
54(20):7066-83.
PMID: 21936542
A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing...
8.
Zimmerlin A, Trunzer M, Faller B
Drug Metab Dispos
. 2011 Mar;
39(6):1039-46.
PMID: 21383203
Although reversible CYP3A inhibition testing is well established for predicting the drug-drug interaction potential of clinical candidates, time-dependent inhibition (TDI) has become the focus of drug designers only recently. Failure...
9.
Jin Y, Zollinger M, Borell H, Zimmerlin A, Patten C
Drug Metab Dispos
. 2010 Nov;
39(2):191-8.
PMID: 21045201
Fingolimod (FTY720, Gilenya, 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol) is a novel drug recently approved in the United States for the oral treatment of relapsing multiple sclerosis. The compound is eliminated predominantly by ω-hydroxylation, followed...
10.
Trunzer M, Faller B, Zimmerlin A
J Med Chem
. 2008 Dec;
52(2):329-35.
PMID: 19108654
Metabolic stability is a key property to enable drugs to reach therapeutic concentrations. Microsomal clearance assays are used to dial out labile compounds in early discovery phases. However, because they...